ChiCTR2600122129 版本V1.0 版本创建时间2026/04/09 10:52:08 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600122129 

最近更新日期:

Date of Last Refreshed on:

2026-04-09 10:52:02 

注册时间:

Date of Registration:

2026-04-09 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

顺逆行双镜联合与单通道经皮肾镜Ⅰ期治疗复杂上尿路结石的疗效比较

Public title:

Comparative Efficacy of One-stage Anterograde-Retrograde Dual Endoscopic Surgery versus Single-tract Percutaneous Nephrolithotomy for Complex Upper Urinary Tract Stones

注册题目简写:

English Acronym:

研究课题的正式科学名称:

顺逆行双镜联合与单通道经皮肾镜Ⅰ期治疗复杂上尿路结石的疗效比较

Scientific title:

Comparative Efficacy of One-stage Anterograde-Retrograde Dual Endoscopic Surgery versus Single-tract Percutaneous Nephrolithotomy for Complex Upper Urinary Tract Stones

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陶波 

研究负责人:

陶波 

Applicant:

Bo Tao 

Study leader:

Bo Tao 

申请注册联系人电话:

Applicant telephone:

+86 135 2915 1395

研究负责人电话:

Study leader's
telephone:

+86 135 2915 1395

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

tb13529151395@163.com

研究负责人电子邮件:

Study leader's E-mail:

tb13529151395@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

昆明市安宁市钢河南路2号

研究负责人通讯地址:

昆明市安宁市钢河南路2号

Applicant address:

No.2, South Steel River Road, Anning

Study leader's address:

No.2, South Steel River Road, Anning

申请注册联系人邮政编码:

Applicant postcode:

650320

研究负责人邮政编码:

Study leader's postcode:

650320

申请人所在单位:

昆明理工大学附属安宁市第一人民医院

Applicant's institution:

The Affiliated Anning First People's Hospital, Kunming University of Science and Technology

研究负责人所在单位:

昆明理工大学附属安宁市第一人民医院

Affiliation of the Leader:

The Affiliated Anning First People's Hospital, Kunming University of Science and Technology

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025-062(自-纵)-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

安宁市第一人民医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the First People's Hospital of Anning

伦理委员会批准日期:

Date of approved by ethic committee:

2025-11-18 00:00:00

伦理委员会联系人:

田蜜

Contact Name of the ethic committee:

Mi Tian

伦理委员会联系地址:

昆明市安宁市钢河南路2号

Contact Address of the ethic committee:

No.2, South Steel River Road, Anning

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 151 9885 7786

伦理委员会联系人邮箱:

Contact email of the ethic committee:

ynkgyyllwyh@163.com

研究实施负责(组长)单位:

安宁市第一人民医院

Primary sponsor:

The First People's Hospital of Anning

研究实施负责(组长)单位地址:

昆明市安宁市钢河南路2号

Primary sponsor's address:

No.2, South Steel River Road, Anning

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

云南省

市(区县):

Country:

China

Province:

Yunnan

City:

单位(医院):

昆明市卫生健康委员会

具体地址:

昆明市呈贡区景秀大街1号

Institution
hospital:

Kunming Health Committee

Address:

No.1 Jingxiu Street, Chenggong District,Kunming

经费或物资来源:

昆明健康委员会研究项目

Source(s) of funding:

Health Research Project of Kunming Health Commission

研究疾病:

泌尿系结石  

Target disease:

Urinary calculi

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1、通过此研究,证实Ⅰ期顺逆行双镜联合手术在复杂性上尿路结石治疗中的优势。 2、为上尿路复杂性结石治疗验证一种安全、有效的治疗方式,最终目标是提高本区域内泌尿系上尿路复杂结石I期清除率,减少患者住院次数,缩短住院时间,减轻患者经济负担。  

Objectives of Study:

1.Through this study, to demonstrate the superiority of one-stage anterograde-retrograde dual endoscopic surgery in the treatment of complex upper urinary tract stones. 2.To validate a safe and effective treatment modality for complex upper urinary tract stones, with the ultimate goals of improving the single-session stone clearance rate within our region, reducing the number of hospital admissions, shortening the length of hospital stay, and alleviating the economic burden on patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

铸型肾结石(结石位于肾盂,分支进入肾盏)、多发性肾结石(≥2枚结石)、巨大肾结石(直径>2.5cm),经B超、KUB+IVP、CT三维成像、尿常规等检查,诊断明确,术前检查完善,患者知情同意,具有明确的手术适应证,无相关手术禁忌证。

Inclusion criteria

Patients with staghorn calculi (stones located in the renal pelvis with branches extending into the calyces), multiple renal calculi (≥2 stones), or large renal calculi (diameter >2.5cm), who have a confirmed diagnosis through examinations such as B-ultrasound, KUB + IVP, three-dimensional CT imaging, and urinalysis, with complete preoperative assessments, informed consent, clear surgical indications, and no relevant surgical contraindications.

排除标准:

合并心、脑、肺、肝、肾等重要脏器功能障碍,难以耐受手术;原发性高血压、糖尿病等疾病未控制;未控制的急性尿路感染、肾积脓、结核活动期;游走肾、移植肾、重度肾下垂、肾盂输尿管连接部狭窄。

Exclusion criteria:

Patients with dysfunction of vital organs (such as cardiac, cerebral, pulmonary, hepatic, or renal) that precludes tolerance for surgery; uncontrolled primary conditions like hypertension or diabetes; uncontrolled acute urinary tract infection, pyonephrosis, or active tuberculosis; or those with conditions including mobile kidney, transplanted kidney, severe nephroptosis, or ureteropelvic junction obstruction.

研究实施时间:

Study execute time:

From 2025-10-01 00:00:00 To 2027-12-09 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-05-01 00:00:00 To 2026-12-31 00:00:00

干预措施:

Interventions:

组别:

顺行经皮肾镜联合逆行软镜组

样本量:

35

Group:

Antegrade Percutaneous Nephrolithotomy Combined with Retrograde Flexible Ureteroscopy Group

Sample size:

干预措施:

患者被随机分为两组,此组患者采用的是顺行单通道经皮肾镜联合逆行软镜治疗。

干预措施代码:

Intervention:

Patients were randomly allocated into two groups. This group underwent treatment with a combined approach of antegrade single-tract percutaneous nephrolithotomy and retrograde flexible ureteroscopy.

Intervention code:

组别:

单通道经皮肾镜组

样本量:

35

Group:

Single-tract Percutaneous Nephrolithotomy Group

Sample size:

干预措施:

患者被随机分为两组,此组患者采用的是顺行单通道经皮肾镜治疗。

干预措施代码:

Intervention:

Patients were randomly allocated into two groups, with this group undergoing treatment via antegrade single-tract percutaneous nephrolithotomy.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

云南省 

市(区县):

昆明 

Country:

China

Province:

Yunnan Province

City:

Kunming

单位(医院):

昆明理工大学附属安宁市第一人民医院 

单位级别:

三级甲等 

Institution
hospital:

The Affiliated Anning First People's Hospital, Kunming University of Science and Technology

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

一期手术结石清除率

指标类型:

主要指标

Outcome:

Single-session stone-free rate

Type:

Primary indicator

测量时间点:

测量方法:

术后第二天进行CT复查

Measure time point of outcome:

Measure method:

Patients underwent a CT scan for assessment on the second postoperative day.

指标中文名:

术后并发症

指标类型:

副作用指标

Outcome:

Postoperative complications

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术中出血量

指标类型:

次要指标

Outcome:

Intraoperative blood loss

Type:

Secondary indicator

测量时间点:

测量方法:

血红蛋白变化值

Measure time point of outcome:

Measure method:

Hemoglobin change

指标中文名:

住院时间

指标类型:

主要指标

Outcome:

Length of hospital stay

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术时间

指标类型:

次要指标

Outcome:

Operative time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究拟对安宁市医共体泌尿外科一段时间内(2026.1.1-2026.12.30)诊断为复杂上尿路结石并且需行PCNL手术的患者,根据纳入及排除标准,资料收集者采用在线随机化工具(https://online-random.com/cn/)将研究患者按1:1的比例分配到顺行经皮肾镜联合逆行软镜组或单通道经皮肾镜组产生随机序列。

Randomization Procedure (please state who generates the random number sequence and by what method):

This study plans to enroll patients diagnosed with complex upper urinary tract stones within the Anning City Medical Consortium's Urology Department during a specified period (January 1, 2026, to December 30, 2026) and scheduled for PCNL. Based on the inclusion and exclusion criteria, the data collector will use an online randomization tool (https://online-random.com/cn/) to allocate enrolled patients in a 1:1 ratio to either the combined antegrade percutaneous nephrolithotomy with retrograde flexible ureteroscopy group or the single-tract percutaneous nephrolithotomy group, thereby generating the random sequence.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

本研究对患者和手术医师不设盲。主要结局(术后CT结石清除率)将由对分组信息不知情的独立影像学专家评估。数据录入与统计分析阶段也将对分组保持盲态。

Blinding:

Neither the patients nor the operating surgeons were blinded in this study. The primary outcome (postoperative CT single-session stone-free rate) will be assessed by an independent radiologist who is blinded to group allocation. Blinding will also be maintained for personnel involved in data entry and statistical analysis.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床研究电子管理公共平台 ResMan:http://www.medresman.org.cn

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Public Platform for Electronic Management of Clinical Research ResMan: http://www.medresman.org

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-04-09 10:52:02